Navigation Links
Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients

- As previously announced, primary endpoint not met; plausibly confounded by survival benefit of post-study treatment with ERBITUX -

NEW YORK, April 16, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced detailed results from the EPIC study - a randomized, open-label, multi-center Phase III trial - comparing ERBITUX(R) (Cetuximab) plus irinotecan to irinotecan alone in patients with metastatic colorectal cancer (mCRC) who failed first-line therapy. Results showed that the secondary endpoints of progression-free survival and response rate were significantly higher in the ERBITUX-irinotecan arm. The median time of survival without disease progression was improved by 54% in the patients who received ERBITUX plus irinotecan. This benefit produced a significant 31% reduction in the risk of disease progression (Hazard ratio, 0.692; 95% CI = 0.617- 0.776; p<0.0001). Additionally, patients in the ERBITUX-irinotecan arm were four times more likely to experience a 50% reduction in tumor size over patients treated with irinotecan alone (p<0.0001).

"The improvement in progression-free survival and response rate expands our understanding of the significant activity of ERBITUX," said Eric Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems. "We believe these outcomes add to the existing clinical evidence demonstrating the safety and effectiveness of ERBITUX in combination with chemotherapy."

As previously reported, the study's primary endpoint of overall survival was not different between the two groups (Hazard ratio, 0.975; 95.03% CI = 0.854 - 1.114; p=0.7115). Analysis of the data show that a considerable number of patients randomized to the irinotecan arm went on to receive ERBITUX with or without irinotecan after failing irinotecan alone. Extensive post-trial use of ERBITUX may explain the lack of difference in overall
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/2/2015)... 2015   Voalte , the leader in healthcare ... $17 million by Ascension Ventures , Cerner Capital, ... Series D funding closed on July 27, 2015, bringing ... million in three years. The new capital ... for Voalte. The privately held company grew revenue by ...
(Date:9/1/2015)... The latest clinical trial ... review of H2, 2015 provides an overview of ... enhance decision making capabilities of active stakeholders in ... market clinical trials review spread across 72 pages, ... organizations and supported with 43 tables and 21 ...
(Date:9/1/2015)... Delaware , United States , Sept. ... "Invion"), is pleased to announce that it has entered into ... investor in the United States in ... million ("Placement") by the issue of 71,500,000 million fully-paid ordinary ... The Company has also agreed to grant ...
Breaking Medicine Technology:Voalte Raises $17 Million in Series D Financing 2Voalte Raises $17 Million in Series D Financing 3Voalte Raises $17 Million in Series D Financing 4Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 2Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 3Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 4Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 5Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3
... N.C., Feb. 21, 2012  Inclinix, Inc. and JSW Life Sciences ... Inclinix offices in Graz, Austria and expands Inclinix by ... Europe. "As Inclinix has experienced significant growth ... us to identify a European partner that shares our ...
... VEGAS, Feb. 21, 2012  NewCrop LLC has ... identity services for NewCrop,s new electronic system ... will integrate Verizon,s tailored digital identity solution, ... enable customers to submit electronic prescriptions for ...
Cached Medicine Technology:Inclinix, Inc. and JSW Life Sciences Announce Formal Strategic Partnership for European Clinical Trial Enrollment 2NewCrop Chooses Verizon to Help Provide Secure Electronic Prescriptions for Controlled Substances 2NewCrop Chooses Verizon to Help Provide Secure Electronic Prescriptions for Controlled Substances 3
(Date:9/2/2015)... , ... September 02, 2015 , ... Ericson is a ... Education Director for HCPro and Associate Director of Education for the Association for Clinical ... CDI and ICD-10 for CDI Boot Camps. She serves as a CDI subject matter ...
(Date:9/2/2015)... ... ... Every year at this time, students prepare to go back to school. ... the academic workload confronting them. They just don’t have the skills needed to do ... students how to study. , “Bankers bank. Salesmen sell. Teachers teach. The job of ...
(Date:9/2/2015)... City, KS (PRWEB) , ... September 02, 2015 , ... ... opened its newest office in Kansas – its Johnson County location. Amada ... in healthcare. Mike has a registered nurse background and spent over 20 years in ...
(Date:9/2/2015)... North Las Vegas, NV (PRWEB) , ... September ... ... in Las Vegas and Fort Lauderdale, CENTURION SERVICE GROUP is internationally known as ... the largest medical auction house in the world, selling more than 100,000 pieces ...
(Date:9/2/2015)... ... 02, 2015 , ... On September 9, 2015, over 27,000 people from all ... single-company convention to date for the state of Utah. , “We are thrilled with ... states David Stirling, doTERRA CEO. “One of the most exciting elements of our convention ...
Breaking Medicine News(10 mins):Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2
... Dec. 1 The Kerlan Jobe Orthopaedic Clinic, a sports ... United States $3 million to settle allegations that it received ... , The settlement resolves allegations ... of stock option grants, donations to the Kerlan Jobe Foundation, ...
... A scientist who broadened the understanding of how we experience ... -- has won the 2010 University of Louisville Grawemeyer Award ... University in Montreal, was selected for the award from among ... of injury but instead in their brain through a pathway ...
... more likely, British study finds , TUESDAY, Dec. 1 (HealthDay ... to deliver a very preterm baby than more affluent women, ... British study shows. , The University of Leicester research team ... the association between economic status and preterm birth. , For ...
... on computed tomography (CT) imaging of changes in tumors ... bevacizumab may have the potential to predict overall survival, ... of JAMA . The addition of ... with improved survival in patients with stage IV colorectal ...
... ... ... largest national HIV non-profit organizations, is changing its name to HealthHIV and launching a new ... promote the organization’s new vision and expanded capabilities and reach. , , , , ,“HealthHIV ...
... With employee benefit choices becoming more complex, a growing ... during open enrollment season, according to a new survey by ... employers who offer these tools believe they lead employees to ... survey, 45 percent of companies offered employees self-service decision tools ...
Cached Medicine News:Health News:Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations 2Health News:Scientist Who Helps Explain Pain Wins Grawemeyer Award 2Health News:More Preemies Born Among the Poor 2Health News:Criteria based on CT imaging after chemotherapy may help predict survival 2Health News:National HIV Non-Profit Announces New Name 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: